UNICREDIT BANK/PUT/AMGEN/200/0.1/17.12.25 | Market Closed - Börse Stuttgart 14:08:34 2024-06-25 EDT | ||
| 0.5 EUR | -1.96% |
|
| Current month | -21.88% | ||
| 1 month | -23.08% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
AMGEN INC.
| Date | Price | Change |
|---|---|---|
| 24-06-25 | 0.5 | -1.96% |
| 24-06-24 | 0.51 | -8.93% |
| 24-06-21 | 0.56 | -1.75% |
| 24-06-20 | 0.57 | +3.64% |
| 24-06-19 | 0.55 | -8.33% |
Delayed Quote Börse Stuttgart
Last update June 25, 2024 at 02:08 pm
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | PUT |
| Underlying | AMGEN INC. |
| Issuer | 
UniCredit
|
| WKN | HD1H7L |
| ISIN | DE000HD1H7L7 |
| Date issued | 2023-12-28 |
| Strike | 200 $ |
| Maturity | 2025-12-17 (540 Days) |
| Parity | 10 : 1 |
| Emission price | 1.05 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 1.15 € |
|---|---|
| Lowest since issue | 0.42 € |
| Spread | 0.13 € |
| Spread % | 22.41% |
Company Profile
Amgen Inc. is one of the world's leading biotechnology groups. Net sales break down by source of revenue as follows:
- drug sales (94.2%): drugs for treating cancer, metabolic disorders, bone diseases, renal failure, hemophilia, etc.;
- other (5.8%): primarily royalties.
The United States account for 70.3% of net sales.
Sector
-
Consensus: Amgen Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
30
Last Close Price
319.3
USD
Average target price
316.4
USD
Spread / Average Target
-0.90%
- Stock Market
- Warrants
- Warrant
